The global COVID-19 pandemic has put the pharma/biopharma industry in the headlines on a daily basis. Many people compare the COVID-19 pandemic to the Spanish influenza epidemic of 1918. However, aside from their being different diseases, a major difference is the ability of the modern industry to develop and share tests and treatments with unprecedented speed.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
9 June 2020 Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.
3 October 2017 The World Intellectual Property Organization (WIPO) has partnered with trade group the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to boost access to patent information.